{
  "docId": "019dd923-622c-750b-8b9b-7e7228555e88",
  "docSlug": "36c903ba19aa",
  "documentTitle": "Allergan, Inc. (AGN)",
  "authorId": "01_Pershing_Square",
  "authorName": "William Ackman",
  "documentKindSlug": "activist-deck",
  "documentKindLabel": "Activist deck",
  "sourceTypeSlug": "activist_investor",
  "sourceTypeLabel": "Activist investor",
  "presentationDate": "2014-04-22 00:00:00",
  "orientation": "portrait",
  "aspectRatio": 0.70665085,
  "pageNumber": 68,
  "pageCount": 110,
  "prevPage": 67,
  "nextPage": 69,
  "slideType": "executive_summary",
  "function": "summarize",
  "density": "sparse",
  "nDataPoints": 4,
  "notes": null,
  "elementsJson": [
    "headline_text",
    "bullet_list"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-622c-750b-8b9b-7e7228555e88/68",
  "deckHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88",
  "deckJsonHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88.json",
  "deckAnchorHref": "/decks/019dd923-622c-750b-8b9b-7e7228555e88#slide-68",
  "components": [
    {
      "bbox": null,
      "kind": "callout",
      "text": "Pershing Square Will Elect To Receive 100% Stock",
      "attrs": null,
      "subkind": null,
      "toolName": "Visual emphasis",
      "toolSlug": "visual-emphasis",
      "confidence": null,
      "componentId": "019dd952-f5d4-752d-aad1-2067b65ee296",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.8,
        "x": 0.1,
        "y": 0.19
      },
      "kind": "list",
      "text": "Cash Component: $15bn; $48.30 per share (based on fully diluted share count); Barclays and RBC Capital Markets financing commitment for 100% of cash component. Stock Component: Allergan shareholders will own ~43% of the pro-forma company; Exchange ratio: 0.83 Valeant shares for every 1 Allergan share. Pershing Square Will Elect To Receive 100% Stock",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2479b49b-e8ce-48e7-8b4a-4714e44c4635",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.25,
        "x": 0.09,
        "y": 0.09
      },
      "kind": "title",
      "text": "The Transaction",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "52595d5f-e249-45e8-adb5-045bcd66cf92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.02,
        "w": 0.2,
        "x": 0.1,
        "y": 0.14
      },
      "kind": "title",
      "text": "Summary Terms:",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc799c1e-8af1-4339-afa1-cee85076e614",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 69,
      "from": 64,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "96b6da1b-b7fe-4458-b004-ac1d3163a35f",
      "evidence": "The presentation notes that Allergan shareholders may miss out on value creation if the deal is not pursued",
      "position": 1,
      "objective": "To highlight the risks of not pursuing the Valeant acquisition",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}